Kyverna Therapeutics, Inc. Common Stock (KYTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $319.27M
Last updated: Nov 17, 2026 at 11:06 AM ET
Kyverna Therapeutics, Inc. Common Stock (KYTX) Earnings: Report Dates and Results
Kyverna Therapeutics, Inc. Common Stock (KYTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.68, in line with the -$0.68 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KYTX has an expected report date of Mar 24, 2027.
Earnings History
Of the 12 quarters below that had an estimate, KYTX beat 7, missed 3 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 731.58% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.68 | -$0.68 | -$0.77 - -$0.65 | 0.00% | In line | N/A | 5 | 3 up, 1 down | Nov 12, 2026 |
| Jun 30, 2026 | -$0.63 | -$0.67 | -$0.71 - -$0.62 | +5.97% | Beat | N/A | 5 | 3 up, 1 down | Aug 12, 2026 |
| Mar 31, 2026 | -$0.66 | -$0.73 | -$0.83 - -$0.62 | +10.06% | Beat | N/A | 5 | 4 up, 0 down | May 12, 2026 |
| Dec 31, 2025 | -$0.80 | -$0.86 | -$1.15 - -$0.64 | +6.98% | Beat | N/A | 5 | 2 up, 0 down | Mar 26, 2026 |
| Sep 30, 2025 | -$0.85 | -$0.95 | -$0.99 - -$0.86 | +10.53% | Beat | N/A | 5 | 1 up, 1 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.97 | -$1.04 | -$1.18 - -$0.87 | +6.73% | Beat | N/A | 5 | 2 up, 3 down | Aug 12, 2025 |
| Mar 31, 2025 | -$1.03 | -$1.00 | -$1.08 - -$0.87 | -3.00% | Miss | N/A | 5 | 0 up, 2 down | May 13, 2025 |
| Dec 31, 2024 | -$0.87 | -$0.95 | N/A | +8.65% | Beat | N/A | 4 | 0 up, 1 down | Mar 27, 2025 |
| Sep 30, 2024 | -$0.80 | -$0.80 | -$0.83 - -$0.68 | 0.00% | In line | N/A | 5 | 2 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$0.67 | -$0.68 | N/A | +1.47% | Beat | N/A | N/A | N/A | Aug 12, 2024 |
| Mar 31, 2024 | -$1.12 | -$0.96 | N/A | -16.67% | Miss | N/A | N/A | N/A | May 14, 2024 |
| Dec 31, 2023 | -$26.86 | -$3.23 | N/A | -731.58% | Miss | N/A | N/A | N/A | Feb 8, 2024 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.65, after -$3.46 the year before. It was -$26.86 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.65 | N/A |
| Dec 31, 2024 | -$3.46 | N/A |
| Dec 31, 2023 | -$26.86 | N/A |
Frequently Asked Questions About KYTX
When is Kyverna Therapeutics, Inc. Common Stock's next earnings date?
Kyverna Therapeutics, Inc. Common Stock's next earnings report is expected for Mar 24, 2027.
Did KYTX beat earnings estimates last quarter?
Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.68 for the quarter ended Sep 30, 2026, in line with the -$0.68 estimate.
What EPS do analysts expect from KYTX next quarter?
The consensus EPS estimate for Kyverna Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.79 from 8 analysts, with estimates from -$0.97 to -$0.71.
How often does KYTX beat earnings estimates?
Kyverna Therapeutics, Inc. Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.74%.
KYTX pages: Overview, Earnings, Forecast, Financials, Competitors